Moderna and Merck cancer vaccine reduces melanoma recurrence risk by 42% in trial
23 October 2026 · filed under cc40a47dae0c
Moderna and Merck reported detailed trial results on October 22 showing their personalized mRNA cancer vaccine, intismeran autogene, reduced the risk of melanoma recurrence by 42 percent compared with standard treatment alone, according to STAT News. The data were presented in connection with the European Society for Medical Oncology and confirmed that the therapy met its key endpoints in the trial.
The vaccine is manufactured individually for each patient, drawing on the genetic profile of that patient’s own tumor to prompt an immune response against recurrence. STAT News reported the companies’ detailed figures substantiate earlier topline claims made about the therapy’s effect on disease-free survival in patients with high-risk melanoma who had undergone surgical removal of their tumors.
STAT News framed the results as confirmation that the approach, which combines Moderna’s mRNA platform with Merck’s existing immunotherapy, produces a measurable clinical benefit beyond existing standard care. The reduction in recurrence risk was described as a key secondary validation of findings the companies had previously disclosed in summary form, now supported by fuller data released at the oncology meeting.
No additional details on survival duration, side effect rates, or regulatory timeline were included in the material reviewed for this bulletin. STAT News did not report commentary from the trial’s lead investigators beyond the topline recurrence figure cited above.